Literature DB >> 1147733

Hyperphosphatemia and hypocalcemia in Burkitt lymophoma. Complications of chemotherapy.

H D Brereton, T Anderson, R E Johnson, P S Schein.   

Abstract

In two patients, metabolic complications, previously unreported to our knowledge, of severe hyperphosphatemia and hypocalcemia in addition to hyperkalemia nad hyperuricemia were demonstrated after treatment with cyclophosphamide. In one patient, elevated blood and ascites lactate levels were measured. The levels decreased rapidly to normal following chemotherapy. The hyperphosphatemia and hyperkalemia may have been due to rapid tumor lysis and the hypocalcemia may have been caused by the hyperphosphatemia. The reduction in blood and aseties lactate levels may reflect the lysis of anaerobically metabolising tumor cells. Renal dialysis was required in the management of both cases. Because of the potential for cardiac arrythmias related to electrolyte imbalance, it is recommended that whenever possible reanl dialysis be available before treating cases of Burkitt lymphoma with large tumor burden.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1147733

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  Clinical disorders of phosphorus metabolism.

Authors:  G C Yu; D B Lee
Journal:  West J Med       Date:  1987-11

Review 2.  Drug-induced electrolyte abnormalities.

Authors:  E P Brass; W L Thompson
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546

3.  The 'tumour overkill syndrome'. A potentially lethal complication of cancer chemotherapy.

Authors:  M L Slevin; R Bell; A M Cotterill; T A Lister
Journal:  Postgrad Med J       Date:  1981-11       Impact factor: 2.401

4.  Hypophosphatemia accompanying blastic crisis in a patient with malignant lymphoma.

Authors:  J Perek; M Mittelman; U Gafter; M Djaldetti
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.